Sexual interest that has faded / 04
Did PT-141 help women troubled by losing desire?
Lost interest in sex may upset you. Certain women improved, but your own sexual concern may differ.
What is the short answer about lost sexual interest?
Sex may stop appealing to you, and that change can hurt. Women given bremelanotide in two large trials reported greater desire and less related upset [20]. Brain activity changed in a separate test as women viewed sexual material [19]. Vyleesi is the prescription name; PT-141 is the name used in research.
The women had previously wanted sex, then found their loss of interest upsetting. The loss of desire affected different situations and partners, rather than just one. Their monthly periods hadn't ended, the change called menopause. You can't carry their results over to men, erection problems or lasting longer during sex.
Nausea commonly occurs, and blood pressure may go up temporarily [21][22]. The label rules out treatment if blood pressure isn't controlled or you have heart or blood-vessel disease. I'd weigh whether more desire was worth feeling sick. Your health may exclude treatment before you get to that choice.
The medicine affects desire through the brain, beyond changing blood flow. What troubles you sexually may differ from what troubled those women. An unchecked product called PT-141 doesn't gain the tested medicine's proof.
Why does an approved product differ from a research bottle?
Researchers make bremelanotide by joining pieces called amino acids in the lab. Those pieces also make up proteins, and here they form a small loop. The medicine resembles a hormone, a chemical your body makes to direct work elsewhere. Researchers use the name PT-141 for this substance.
The approved product has checks on contents and preparation. Sharing the name doesn't assure those checks for a research product. Your question needs to concern the exact medicine researchers tested.
The medicine's effects on brain activity help explain changes in desire. Approval covers certain women troubled by low desire, rather than every sexual difficulty. The approval doesn't establish help for your sexual concern if that concern differs.
What did the women report after the scan study?
Women given PT-141 described increased desire lasting up to 24 hours [19]. The 31 women found their low desire upsetting, and their periods hadn't ended. Each received bremelanotide at one visit and placebo at another. Researchers compared the answers from the same woman after each treatment.
The placebo looked like the treatment without containing active medicine. Brain activity changed while the women looked at sexual material. Dopamine, a substance carrying messages between brain cells, may help explain the change. That possible explanation can't predict how much difference you'd notice.
In an animal test, female Syrian hamsters learned that mating happened in a particular location [18]. Bremelanotide didn't make them favor that location more strongly. That experiment didn't find an increase in how rewarding mating was for the hamsters. That finding doesn't overturn the separate results reported by women.
How were desire and upset measured over longer studies?
Bremelanotide patients had greater gains in desire and relief from related upset compared with placebo patients [20]. The two larger trials, called phase 3 tests before approval, enrolled 1,267 women before menopause. Women didn't choose their treatment; chance decided during the 24 weeks of testing. RECONNECT was the name of these trials.
Women's answers to questions about desire and upset were turned into scores. Researchers compared the average change in scores for each treatment group. The treated women improved more, with chance an unlikely explanation. An average doesn't show every woman's change in desire, and a gain found by the study questions may still be too small to make a worthwhile difference in your life.
Later, 684 women took part in another 52 weeks of checks [21]. Desire and related upset stayed improved, with no new safety concern found. All knew they received bremelanotide, and there wasn't a placebo group. That leaves more doubt about what kept the improvements going.
The official label describes how the body clears the approved medicine [22]. Your blood pressure can increase temporarily, which the label warns about. You can't judge an unchecked product's safety by what happened with the tested medicine.
What unwanted effects could make greater desire less worthwhile?
People trying the substance describe personal research-use experiences, without a fair trial comparing treatments or checking the cause of a change. Some report greater desire, excitement or sensitivity, while others report no effect. Tiredness, headache, nausea, darker skin and soreness around shots also appear. These personal accounts don't give you reliable chances of experiencing a problem.
During longer checks, 40.4% of women reported nausea, 20.6% reported flushing and 12.0% reported headache [21]. Flushing makes you suddenly feel warm as your skin reddens. The gain in desire may matter less if you feel sick. You need to consider both changes together.
Your blood pressure may rise temporarily, according to the label [22]. The medicine is ruled out for uncontrolled high blood pressure or disease affecting your heart or its blood vessels. Darkened patches of skin are another warning on the label [22]. Men's personal reports don't supply the trial proof found for certain women.
Your existing illnesses could make the medicine unsuitable altogether. Greater desire may not be worth the discomfort to you. A study can't make that personal judgment on your behalf.
Why are men's sexual problems still a separate question?
PT-141 trials concerned women upset by a loss of sexual interest. Semaglutide works differently and treats other health problems. Neither medicine's approval assures help beyond the particular uses studied.
Animal tests, scans, human trials and the label examined different questions [18][19][20][21][22]. The human findings concern desire, related upset and side effects in certain women. Men's erections and lasting longer during sex weren't established benefits.
Your own sexual concern needs research that actually tests that concern. The people studied and their health need to fit your question, too. A brain scan can't fill in a missing trial of benefit.